{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:05:28Z","timestamp":1765209928742,"version":"3.46.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Die verschiedenen Behandlungsstrategien bei Augen mit vitreomakul\u00e4rer Traktion (VMT) und Makulaforamen (MF) sollen hinsichtlich Indikationsstellung und Therapieeinleitung evaluiert werden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ziel der Arbeit<\/jats:title>\n                    <jats:p>Meinungsbild unter erfahrenen Retinologen zur Unterst\u00fctzung der klinischen Entscheidungsfindung im Kontext der aktuellen Literatur und der ver\u00e4nderten Zulassungssituation f\u00fcr Ocriplasmin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material und Methoden<\/jats:title>\n                    <jats:p>In einer Online-Umfrage wurden die Mitglieder der Retinologischen Gesellschaft (RG) befragt. Anhand einer Literaturrecherche wurde ein Fragebogen mit 100 Fragen erstellt und durch den E\u2011Mail-Verteiler der RG per elektronischem Link zur Online-Plattform \u201eLimeSurvey\u201c an alle Mitglieder versendet. Die freiwillige Teilnahme war vom 15.10.2021 bis zum 15.11.2021 m\u00f6glich. Die Datenerhebung sowie die statistische Auswertung erfolgten anonymisiert.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Die Antworten der 115 Teilnehmenden ergaben kongruente Antwortergebnisse, die der Darstellung der neuen S1-Leitlinie zu diesem Thema entsprechen. Die Indikation zur aktiven Therapie einer fokalen VMT ohne MF wurde zugunsten des Abwartens und Beobachtens zur\u00fcckgestellt. Dabei spielte die individuelle Symptomatik des Patienten eine besondere Rolle f\u00fcr das vorgeschlagene zeitliche Management. Die Ergebnisse zur Indikation zur Vitrektomie sind einheitlich und best\u00e4tigen \u00fcberzeugend die Meinungen zur Effektivit\u00e4t und Risikobewertung dieses Therapieverfahrens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diskussion<\/jats:title>\n                    <jats:p>Die dargestellten Ergebnisse geben einen \u00dcberblick \u00fcber Konsens und Kontroversen in den aktuellen Behandlungsm\u00f6glichkeiten bei VMT und MF. Dabei gelang es mithilfe einer homogenen und erfahrenen Gruppe von Netzhautexperten, individuelle Behandlungsstrategien herauszuarbeiten.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphic abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00347-024-02118-1","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T11:42:32Z","timestamp":1727350952000},"page":"973-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update zur Behandlungsstrategie bei vitreomakul\u00e4rer Traktion und Makulaforamen: eine Umfrage unter Retinologen in Deutschland","Current treatment strategies for vitreomacular traction and macular holes: a survey of retinal specialists in Germany"],"prefix":"10.1007","volume":"121","author":[{"given":"D.","family":"Vogt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Haritoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. C.","family":"Kortuem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Deiters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Hoerauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. G.","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"issue":"7","key":"2118_CR1","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s00417-022-05568-y","volume":"260","author":"C Baumann","year":"2022","unstructured":"Baumann\u00a0C, Sabatino\u00a0F, Zheng\u00a0Y et\u00a0al (2022) Anatomical and functional outcomes of pneumatic vitreolysis for treatment of vitreomacular traction with and without macular holes. Graefes Arch Clin Exp Ophthalmol 260(7):2209\u20132215","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"2118_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4103\/jovr.jovr_146_17","volume":"12","author":"CK Chan","year":"2017","unstructured":"Chan\u00a0CK, Mein\u00a0CE, Crosson\u00a0JN (2017) Pneumatic Vitreolysis for Management of Symptomatic Focal Vitreomacular Traction. J\u00a0Ophthalmic Vis Res 12(4):419\u2013423","journal-title":"J Ophthalmic Vis Res"},{"issue":"11","key":"2118_CR3","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.ophtha.2021.05.005","volume":"128","author":"CK Chan","year":"2021","unstructured":"Chan\u00a0CK, Mein\u00a0CE, Glassman\u00a0AR et\u00a0al (2021) Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular traction with and without macular hole: DRCR retina network protocols AG and AH. Ophthalmology 128(11):1592\u20131603","journal-title":"Ophthalmology"},{"issue":"7","key":"2118_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/aos.15682","volume":"101","author":"F Confalonieri","year":"2023","unstructured":"Confalonieri\u00a0F, Haave\u00a0H, Binder\u00a0S et\u00a0al (2023) Macular hole Delphi consensus statement (MHOST). Acta Ophthalmol 101(7):815\u2013825","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"2118_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00347-022-01774-5","volume":"120","author":"Deutsche Ophthalmologische Gesellschaft e.\u202fV. (DOG)","year":"2023","unstructured":"Deutsche Ophthalmologische Gesellschaft e.\u202fV. (DOG), Retinologische Gesellschaft e.\u202fV. (RG), Berufsverband der Augen\u00e4rzte Deutschlands e.\u202fV. (BVA) (2023) Makulaforamen und vitreomakul\u00e4re Traktion: S1-Leitlinie der Deutschen Ophthalmologischen Gesellschaft (DOG), der Retinologischen Gesellschaft (RG) und des Berufsverbands der Augen\u00e4rzte Deutschlands (BVA). Version: 22.\u00a0September 2022. Ophthalmologie 120(1):1\u201314 (Macular hole and vitreomacular traction: S1 guideline of the German Society of Ophthalmology (DOG), the German Retina Society (RG) and the German Professional Association of Ophthalmologists (BVA). Version: 22\u00a0September 2022)","journal-title":"Ophthalmologie"},{"issue":"12","key":"2118_CR6","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1016\/j.ophtha.2013.07.042","volume":"120","author":"JS Duker","year":"2013","unstructured":"Duker\u00a0JS, Kaiser\u00a0PK, Binder\u00a0S et\u00a0al (2013) The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 120(12):2611\u20132619","journal-title":"Ophthalmology"},{"issue":"6","key":"2118_CR7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00347-024-02042-4","volume":"121","author":"H Faatz","year":"2024","unstructured":"Faatz\u00a0H, Hattenbach\u00a0LO, Krohne\u00a0TU et\u00a0al (2024) Vitreomakul\u00e4re Traktion: Diagnostik, nat\u00fcrlicher Verlauf, Therapieentscheidung und Leitlinienempfehlungen. Ophthalmologie 121(6):470\u2013475 (Vitreomacular traction: diagnostics, natural course, treatment decision and guideline recommendations)","journal-title":"Ophthalmologie"},{"issue":"1","key":"2118_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40942-022-00376-2","volume":"8","author":"AN Fouad","year":"2022","unstructured":"Fouad\u00a0AN, Eissa\u00a0IM, Nassar\u00a0GA et\u00a0al (2022) Effect of pneumatic vitreolysis in management of patients with symptomatic focal vitreomacular traction. Int J Retin Vitreous 8(1):22","journal-title":"Int J Retin Vitreous"},{"issue":"7","key":"2118_CR9","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00417-020-04995-z","volume":"259","author":"JH Garcia","year":"2021","unstructured":"Garcia\u00a0JH, Johnson\u00a0M, Shah\u00a0G et\u00a0al (2021) Macular microhole and foveal red spot syndrome: a\u00a0critical review of the literature. Graefes Arch Clin Exp Ophthalmol 259(7):1685\u20131694","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"2118_CR10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1097\/IAE.0000000000003513","volume":"42","author":"A Garg","year":"2022","unstructured":"Garg\u00a0A, Popovic\u00a0M, Cioana\u00a0M et\u00a0al (2022) Predictive factors of spontaneous release of vitreomacular traction: A\u00a0Systematic Review and Meta-Analysis. Retina 42(7):1219\u20131230","journal-title":"Retina"},{"issue":"1","key":"2118_CR11","doi-asserted-by":"publisher","first-page":"18089","DOI":"10.1038\/s41598-021-97639-z","volume":"11","author":"J Guber","year":"2021","unstructured":"Guber\u00a0J, Rusch\u00a0C, Guber\u00a0I et\u00a0al (2021) Indications and outcomes for intravitreal injection of C3F8 gas for symptomatic vitreomacular traction. Sci Rep 11(1):18089","journal-title":"Sci Rep"},{"key":"2118_CR12","unstructured":"https:\/\/www.dog.org\/wp-content\/uploads\/2013\/03\/Stellungnahme_Ocriplasmin.pdf. Zugegriffen: 29. Jan. 2024"},{"key":"2118_CR13","unstructured":"https:\/\/www.kaden-verlag.de\/ueber-uns\/nachrichten\/neues-detail\/vertrieb-von-jetrea-zum-31-dezember-2023-eingestellt. Zugegriffen: 29. Jan. 2024"},{"issue":"10","key":"2118_CR14","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1097\/IAE.0b013e3182a6b3e2","volume":"33","author":"TL Jackson","year":"2013","unstructured":"Jackson\u00a0TL, Nicod\u00a0E, Angelis\u00a0A et\u00a0al (2013) Pars plana vitrectomy for vitreomacular traction syndrome: a\u00a0systematic review and metaanalysis of safety and efficacy. Retina 33(10):2012\u20132017","journal-title":"Retina"},{"issue":"6","key":"2118_CR15","doi-asserted-by":"publisher","first-page":"e823","DOI":"10.1111\/aos.14686","volume":"99","author":"AM Khanani","year":"2021","unstructured":"Khanani\u00a0AM, Constantine\u00a0RN, Blot\u00a0KH et\u00a0al (2021) Effectiveness of ocriplasmin in real-world settings: A\u00a0systematic literature review, meta-analysis, and comparison with randomized trials. Acta Ophthalmol 99(6):e823\u2013e836","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"2118_CR16","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1097\/IAE.0000000000003456","volume":"42","author":"V Kumar","year":"2022","unstructured":"Kumar\u00a0V, Sonkar\u00a0R, Verma\u00a0S et\u00a0al (2022) Pneumatic vitreolysis versus pars plana vitrectomy in focal symptomatic vitreomacular traction syndrome: A\u00a0Randomized Trial. Retina 42(7):1277\u20131283","journal-title":"Retina"},{"issue":"6","key":"2118_CR17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s00347-024-02047-z","volume":"121","author":"JQ Li","year":"2024","unstructured":"Li\u00a0JQ, Hattenbach\u00a0LO, Lommatzsch\u00a0A et\u00a0al (2024) Makulaforamen: Differenzialdiagnose, Behandlungsoptionen und neue Leitlinienempfehlungen. Ophthalmologie 121(6):462\u2013469 (Macular hole: Differential diagnosis, treatment options and new guideline recommendations)","journal-title":"Ophthalmologie"},{"key":"2118_CR18","first-page":"1001","volume":"80","author":"K Markov\u00e1","year":"2024","unstructured":"Markov\u00e1\u00a0K, N\u011bmec\u00a0P, \u010cerven\u00fd\u00a0P et\u00a0al (2024) Pneumatic Vitreolysis using C3F8 Gas in Treatment Naive Patients with Vitreomacular Traction. Cesk Slov Oftalmol 80:1001\u20131008","journal-title":"Cesk Slov Oftalmol"},{"issue":"1","key":"2118_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000516768","volume":"245","author":"ZA Nawrocka Vel Michalewska","year":"2022","unstructured":"Nawrocka Vel Michalewska\u00a0ZA, Nawrocka\u00a0Z, Nawrocki\u00a0J (2022) Spontaneous Closure of Full-Thickness Macular Holes. Ophthalmologica 245(1):49\u201358","journal-title":"Ophthalmologica"},{"key":"2118_CR20","doi-asserted-by":"crossref","unstructured":"Neubauer J, Gelisken F, Ozturk T et\u00a0al (2024) The time course of spontaneous closure of idiopathic full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol","DOI":"10.1007\/s00417-024-06465-2"},{"key":"2118_CR21","doi-asserted-by":"crossref","unstructured":"Parravano M, Giansanti F, Eandi CM et\u00a0al (2015) Vitrectomy for idiopathic macular hole. Cochrane Database Syst Rev: CD9080","DOI":"10.1002\/14651858.CD009080.pub2"},{"issue":"10","key":"2118_CR22","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.oret.2022.04.021","volume":"6","author":"V Patel","year":"2022","unstructured":"Patel\u00a0V, Kiryakoza\u00a0L, Chau\u00a0V et\u00a0al (2022) Idiopathic Vitreomacular Traction Managed with Initial Observation: Clinical Course and Outcomes. Ophthalmol Retina 6(10):893\u2013898","journal-title":"Ophthalmol Retina"},{"key":"2118_CR23","doi-asserted-by":"publisher","first-page":"9457670","DOI":"10.1155\/2020\/9457670","volume":"2020","author":"P Petrou","year":"2020","unstructured":"Petrou\u00a0P, Chalkiadaki\u00a0E, Errera\u00a0MH et\u00a0al (2020) Factors Associated with the Clinical Course of Vitreomacular Traction. J\u00a0Ophthalmol 2020:9457670","journal-title":"J Ophthalmol"},{"issue":"1","key":"2118_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40942-023-00472-x","volume":"9","author":"MA Quiroz-Reyes","year":"2023","unstructured":"Quiroz-Reyes\u00a0MA, Quiroz-Gonzalez\u00a0EA, Quiroz-Gonzalez\u00a0MA et\u00a0al (2023) Pneumatic vitreolysis versus vitrectomy for the treatment of vitreomacular traction syndrome and macular holes: complication analysis and systematic review with meta-analysis of functional outcomes. Int J Retina Vitreous 9(1):33","journal-title":"Int J Retina Vitreous"},{"issue":"1","key":"2118_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40942-022-00439-4","volume":"9","author":"FA Rezende","year":"2023","unstructured":"Rezende\u00a0FA, Ferreira\u00a0BG, Rampakakis\u00a0E et\u00a0al (2023) Surgical classification for large macular hole: based on different surgical techniques results: the CLOSE study group. Int J Retin Vitreous 9(1):4","journal-title":"Int J Retin Vitreous"},{"issue":"11","key":"2118_CR26","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s00417-017-3747-1","volume":"255","author":"RG Schumann","year":"2017","unstructured":"Schumann\u00a0RG, Langer\u00a0J, Compera\u00a0D et\u00a0al (2017) Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice. Graefes Arch Clin Exp Ophthalmol 255(11):2081\u20132089","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"2118_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ophtha.2013.10.020","volume":"121","author":"K Spiteri Cornish","year":"2014","unstructured":"Spiteri Cornish\u00a0K, Lois\u00a0N, Scott\u00a0NW et\u00a0al (2014) Vitrectomy with internal limiting membrane peeling versus no peeling for idiopathic full-thickness macular hole. Ophthalmology 121(3):649\u2013655","journal-title":"Ophthalmology"},{"issue":"1","key":"2118_CR28","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41433-020-0844-x","volume":"35","author":"DH Steel","year":"2021","unstructured":"Steel\u00a0DH, Donachie\u00a0PHJ, Aylward\u00a0GW et\u00a0al (2021) Factors affecting anatomical and visual outcome after macular hole surgery: findings from a\u00a0large prospective UK cohort. Eye 35(1):316\u2013325","journal-title":"Eye"},{"issue":"2","key":"2118_CR29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/IAE.0000000000002862","volume":"41","author":"DHW Steel","year":"2021","unstructured":"Steel\u00a0DHW, Patton\u00a0N, Stappler\u00a0T, INJECT study investigators et\u00a0al (2021) Ocriplasmin for vitreomacular traction in clinical practice: The INJECT Study. Retina 41(2):266\u2013276","journal-title":"Retina"},{"issue":"2","key":"2118_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/IAE.0000000000003943","volume":"44","author":"Q Yang","year":"2024","unstructured":"Yang\u00a0Q, Huang\u00a0X, Peng\u00a0R et\u00a0al (2024) Correlations between suspended hyperreflective material with the macular microstructure and spontaneous closure of full-thickness macular holes. Retina 44(2):237\u2013245","journal-title":"Retina"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02118-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-024-02118-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02118-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T15:58:00Z","timestamp":1765209480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-024-02118-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2118"],"URL":"https:\/\/doi.org\/10.1007\/s00347-024-02118-1","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"type":"print","value":"2731-720X"},{"type":"electronic","value":"2731-7218"}],"subject":[],"published":{"date-parts":[[2024,9,26]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dieser Artikel wurde urspr\u00fcnglich im Abonnement-Modell ver\u00f6ffentlicht, wird jedoch jetzt unter einer Open-Access-Lizenz ver\u00f6ffentlicht.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0Vogt ist als Referentin f\u00fcr die Firma AbbVie Deutschland GmbH & Co.KG, Novartis Pharma GmbH und Bayer Vital GmbH t\u00e4tig und erh\u00e4lt dabei ein Beraterhonorar. H.\u00a0Hoerauf ist als Referent f\u00fcr die Firmen Alcon, AbbVie, Biogen, Bayer, Heidelberg Engineering, Novartis, Roche, Stadapharm und Thea Pharma t\u00e4tig und erh\u00e4lt dabei ein Beraterhonorar. R.G.\u00a0Schumann ist als Referentin f\u00fcr die Firma AbbVie Deutschland GmbH & Co.KG, Novartis Pharma GmbH, Bayer Vital GmbH und Carls Zeiss AG t\u00e4tig und erh\u00e4lt dabei ein Beraterhonorar. C.\u00a0Haritoglou, V.\u00a0Nicoletti, F.C.\u00a0Kortuem, V.\u00a0Deiters und A.\u00a0Wolf geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}